Home > News > Industry > Pharma News > Biocon net profit up 31...

Biocon net profit up 31 percent in Q4

By - Ruchika Sharma
Published On 2023-05-24 09:00 GMT   |   Update On 2023-05-24 10:26 GMT

New Delhi: Global biopharmaceuticals company Biocon has announced its consolidated financial results for the fourth quarter and the fiscal year that ended on March 31, 2023.The company's revenue from operations during the January-March quarter and for the entire 2022-23 was Rs 3774 and Rs 11174 crore, up 57 per cent and 37 per cent, respectively, on a yearly basis.Its consolidated net profits...

Login or Register to read the full article
Register Now

New Delhi: Global biopharmaceuticals company Biocon has announced its consolidated financial results for the fourth quarter and the fiscal year that ended on March 31, 2023.

The company's revenue from operations during the January-March quarter and for the entire 2022-23 was Rs 3774 and Rs 11174 crore, up 57 per cent and 37 per cent, respectively, on a yearly basis.
Its consolidated net profits for the quarter and the full fiscal year were Rs 313 crore and Rs 463 crore, up 31 per cent and down 29, respectively.
"The Generics business performance in FY23 was in line with our expectations, delivering healthy year-on-year revenue growth that was driven by immunosuppressants, specialty APIs, and a ramp-up of some of our recently launched generic formulation products," said Siddharth Mittal, CEO and Managing Director, Biocon Limited.
"Profitability for the year was muted, mainly on account of pricing pressure in our key markets, as well as increased input costs, that was partially mitigated by cost improvement initiatives," said Mittal.
Along with the earnings, the Board of Directors has recommended a final dividend of Rs 1.50 per share for the financial year that ended March 31, 2023.
A dividend is a reward that companies often provide to their shareholders, though not mandatory, from a portion of their earnings.

Biocon Limited is an Indian biopharmaceutical company headquartered in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S. and Europe. It also has a pipeline of novel assets in immunotherapy under development. Biocon’s biosimilars business is through its subsidiary, Biocon Biologics Ltd.

Read also: Biocon Biologics Bengaluru facility gets EU GMP certification for Bevacizumab

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Use MvPI platform for reporting any adverse events linked to medical devices: CDSCO
CDSCO panel noted Biological E's Post Marketing Surveillance Report of Monovalent recombinant Hepatitis-B vaccine
Boehringer Ingelheim Spevigo injection for generalized pustular psoriasis flares gets CDSCO nod
Zydus Lifesciences appoints Shelina Parikh as Additional Director, Independent Director
Zydus Lifesciences arm, MSN Labs collaborate to license, supply cancer drug Cabozantinib in US
Dr Reddy's Labs gets 2 USFDA observations for Duvvada facilities
SII makes strategic investment in IntegriMedical, India's First Needle-Free Injection System Technology
ICMR invites EoI for joint development, commercialization of Salmonella vaccine